To develop and manufacture a GMP-grade TMCP2 gonococcal vaccine candidate and advance the candidate through a phase I clinical trial.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00049
- Awardee
-
University Of Massachusetts Medical School UEI MQE2JHHJW9Q8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,842,170
Award facts
- Opportunity
-
- 2019 NIAID Omnibus Broad Agency Announcement Special Notice · HHSNIHNIAIDBAA20191 · Posted Jan 29, 2019
- HHS-NIH-NIAID-BAA2019-1: Research Area 003, Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria Award Notice · Posted Aug 28, 2020
- 2019 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · Posted Feb 22, 2019
- Contract value 54% obligated
-
- $3,842,169.74 Current, with exercised options
- $7,168,672.74 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Worcester, MA 01655, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$285,485 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $538,022 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $704,939 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $606,797 | |
| Exercise an Option | $258,071 | |
| Original award | $2,019,826 |
Show all 14
About this award
The National Institute of Allergy and Infectious Diseases awarded a definitive contract to University Of Massachusetts Medical School for development and manufacturing of a GMP-grade TMCP2 gonococcal vaccine candidate and advancement through Phase I clinical trial, with a ceiling value of $7,168,672.74 on September 1, 2020.
The contract carries cost-plus-no-fee pricing and no set-aside. Place of performance is Worcester, MA. The underlying solicitation was a Broad Agency Announcement from NIAID seeking proposals for radiation and nuclear medical countermeasures; the posted opportunity (posted January 29, 2019) anticipated awards of up to $4 million per year to one to two contractors. The ultimate completion date is February 28, 2025.
Service Contract Inventory data shows the contract invoiced $914 thousand in FY2021, declining to $45 thousand in FY2025 (the most recent reported year, reflecting 0.0 FTEs and 22 contractor hours). FY2022 posted the highest activity at $1.1 million invoiced across 0.7 FTEs and 1,402 contractor hours. Government-paid hourly rates rose from $771.13 in FY2022 to $2,072.51 in FY2025. One subcontractor was reported in FY2025.
Quick answers
Who was awarded contract 75N93020C00049?
75N93020C00049 was awarded to University Of Massachusetts Medical School by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2020.
How much is contract 75N93020C00049 worth?
The government has obligated $3,842,170 on 75N93020C00049. Its potential value, with all options, is $7,168,673.
Was contract 75N93020C00049 competed?
The extent of competition for 75N93020C00049 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award